SCHEMBL5455957

SCHEMBL5455957

CC(C)(C)OC(=O)N1CCN(c2ccc(NC(=O)Nc3nc(C(C)(C)C)cs3)cn2)CC1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
WNT3A P56704 1/20 0.51
MAPK1 P28482 2/20 0.50
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50
SMN1; SMN2 Q16637 2/20 0.50
ALDH1A1 P00352 2/20 0.50
DDB1 Q16531 1/20 0.50
CRBN Q96SW2 1/20 0.50
NPC1 O15118 1/20 0.50
POLB P06746 1/20 0.50
RAB9A P51151 1/20 0.50
FLT3 P36888 1/20 0.47
TBK1 Q9UHD2 1/20 0.46
GPR119 Q8TDV5 3/20 0.45
CKS1B P61024 2/20 0.44
SKP1 P63208 2/20 0.44
SKP2 Q13309 2/20 0.44
MAPT P10636 2/20 0.44
TSHR P16473 1/20 0.44
MAP4K4 O95819 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5551064 0.89 MAPK1 (0.56) MAPK1MEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL5467445 0.87 MEN1 (0.56) MAPK1MEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL5460908 0.84 RAB9A (0.55) MAPK1MEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL5452148 0.83 WNT3A (0.52) WNT3AMEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL5454381 0.81 NPC1 (0.47) MAPK1MEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL24590342 0.77 DDB1 (0.63) WNT3AMEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL5471069 0.77 ALDH1A1 (0.54) WNT3AMEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL5473462 0.77 DGAT1 (0.53) WNT3ADDB1CRBNGPR119CKS1B
SCHEMBL3185809 0.77 MAPK14 (0.61) BRAF
SCHEMBL3545383 0.76 DDB1 (0.58) WNT3AMEN1KMT2ASMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070249620-A1 Urea Derivative SANKYO COMPANY, LIMITED (JP) 2007-10-25 US disclosed
EP-1764360-A1 UREA DERIVATIVE Sankyo Company, Limited (JP) 2007-03-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070249620-A1 Urea Derivative UGP2, SLC14A1, DGAT1 WNT3A 3010/4885MAPK1 1466/4885MEN1 1828/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.